Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Posttraumatic Stress Disorder
      • Long Covid
      • Cocaine Intoxication
      • Migraine
      • Depression
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Monkeypox
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-601 ER
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-1850
      • TNX-801
    • Rare Disease
      • TNX-2900
    • Scientific Presentations
    • Expanded Access Policy
  • Clinical Trials
  • News & Events
    • Tonix in the News
    • Press Releases
    • Investor Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix is enrolling in a Phase 3 study for Fibromyalgia, and Phase 2 studies for Chronic Migraine and Major Depressive Disorder. Please visit Clinical Trials.

Multimedia

Investors

Investors

  • Overview
  • News & Events
    • Tonix in the News
    • Press Releases
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
A Nasal Spray to Curb Excessive Eating in Prader-Willi
May 11, 2023

A Nasal Spray to Curb Excessive Eating in Prader-Willi

Tonix Pharmaceuticals TNX-1500 monoclonal antibody published in American Journal of Transplantation
Apr 21, 2023

Tonix Pharmaceuticals TNX-1500 monoclonal antibody published in American Journal of Transplantation

Tonix signs agreement with UMB to use monoclonal antibodies in preventing heart transplant rejection
Feb 27, 2023

Tonix signs agreement with UMB to use monoclonal antibodies in preventing heart transplant rejection

Tonix Pharmaceuticals announces acquisition of Healion Bio antiviral portfolio
Feb 23, 2023

Tonix Pharmaceuticals announces acquisition of Healion Bio antiviral portfolio

Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies
Feb 1, 2023

Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies

Seth Lederman, Co-Founder, CEO & Chairman of Tonix Pharmaceuticals discusses the state of Covid-19 in the U.S. and China
Jan 9, 2023

Seth Lederman, Co-Founder, CEO & Chairman of Tonix Pharmaceuticals discusses the state of Covid-19 in the U.S. and China

Tonix Pharmaceuticals says IND application for TNX-601 to treat depression is a major milestone
Oct 6, 2022

Tonix Pharmaceuticals says IND application for TNX-601 to treat depression is a major milestone

 Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King
Aug 31, 2022

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King
Aug 16, 2022

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by Bloomberg Radio
Aug 12, 2022

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by Bloomberg Radio

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King
Jun 9, 2022

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King
May 6, 2022

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King

Tonix Pharmaceuticals CEO talks through 2021 highlights, ending year with $179M in cash
Mar 25, 2022

Tonix Pharmaceuticals CEO talks through 2021 highlights, ending year with $179M in cash

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King
Feb 11, 2022

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King
Dec 11, 2021

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King

Tonix begins work at its Infectious Disease R&D Center in Maryland, discusses RELIEF results
Nov 17, 2021

Tonix begins work at its Infectious Disease R&D Center in Maryland, discusses RELIEF results

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King
Oct 5, 2021

Interview with Dr. Seth Lederman, CEO of Tonix Pharmaceuticals (NASDAQ: TNXP), by journalist Jane King

Tonix Pharma CEO discusses Phase 3 RALLY study results and intent to acquire new R&D facility
Aug 23, 2021

Tonix Pharma CEO discusses Phase 3 RALLY study results and intent to acquire new R&D facility

Tonix Pharmaceuticals CEO Seth Lederman returns to New to the Street
Aug 6, 2021

Tonix Pharmaceuticals CEO Seth Lederman returns to New to the Street

Tonix Pharmaceuticals to develop therapeutic to treat Long COVID Syndrome
Jul 15, 2021

Tonix Pharmaceuticals to develop therapeutic to treat Long COVID Syndrome

rss_feed RSS
  • Page 1
  • Page 2
  • Page 3
  • Next Pagearrow_forward
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2023 Tonix Pharmaceuticals Holding Corp.